<DOC>
	<DOCNO>NCT00877656</DOCNO>
	<brief_summary>The purpose study assess safety efficacy treatment non-cutaneous T-cell lymphoma treatment CD4 .</brief_summary>
	<brief_title>HuMax-CD4 Non-Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description>The study close subject complete treatment . The study evaluate safety efficacy Humax CD4 CHO v CHO alone subject non-cutaneous T cell lymphoma . The primary efficacy evaluate time relapse .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnostic biopsy non cutaneous T Cell lymphoma positive phenotype Relapsed refractory minimum one course chemotherapy Study close enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>